Hypera SA banner

Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 23.42 BRL 1.69% Market Closed
Market Cap: R$16.5B

Hypera SA
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Hypera SA
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Hypera SA
BOVESPA:HYPE3
Inventory
R$2.1B
CAGR 3-Years
-2%
CAGR 5-Years
18%
CAGR 10-Years
18%
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Inventory
R$410m
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
14%
No Stocks Found

Hypera SA
Glance View

Market Cap
16.5B BRL
Industry
Pharmaceuticals

Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.

HYPE3 Intrinsic Value
29.36 BRL
Undervaluation 20%
Intrinsic Value
Price R$23.42

See Also

What is Hypera SA's Inventory?
Inventory
2.1B BRL

Based on the financial report for Dec 31, 2025, Hypera SA's Inventory amounts to 2.1B BRL.

What is Hypera SA's Inventory growth rate?
Inventory CAGR 10Y
18%

Over the last year, the Inventory growth was 7%. The average annual Inventory growth rates for Hypera SA have been -2% over the past three years , 18% over the past five years , and 18% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett